With all due respect Mr Mainstreet, there are many Amarin shareholders who have a much higher price per share avg than you. They would not be happy with a 12 dollar buyout. I believe that what HDG is seeing and I also is that the share price will not be a factor in any BO negotiation. With NCE, 1st amendment win, Patents and a positive reduce-it any BO price will be determined by future revenue to be generated by Vascepa. I have heard many figures on what the current statin market yields per year, anywhere 40-60 billion worldwide. With positive reduce-it adding Vascepa to statins that will be the revenue that will be negotiated in any BO talks. Just my take but that is how I see it.